Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the U.S. Food and Drug Administration Adverse Event Reporting System

19 december 2022
door American Diabetes Association - Care

CAMS Innovation Fund for Medical Sciences2021-1-I2M-002National Natural Science Foundation of China10.13039/50110000180991846106Beijing Natural Science FoundationM22014Training Program for Excellent TalentsTPETDD2018Chinese Academy of Medical Sciences10.13039/5011000051502019XK320029

Bekijk het originele bericht

Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the U.S. Food and Drug Administration Adverse Event Reporting System

Wellicht vindt u dit ook interessant

Meld u aan voor de maandelijkse nieuwsbrief

Categorieën

Patiëntvoorbeelden m.b.t. vergoeding

Voeg je koptekst hier toe

Vergoeding diabetesmiddelen